Scisparc initiated its clinical trial with sci-210 in pediatrics with autism spectrum disorder

Tel aviv, israel, sept. 29, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, today announced the initiation of a pivotal clinical trial for its drug candidate, sci-210, at the soroka university medical center. sci-210 is designed to help control symptoms of autism spectrum disorder (“asd”) and is an innovative proprietary combination of cannabidiol (“cbd”) and scisparc's palmitoylethanolamide (pea), the active ingredient of its proprietary cannamide™.
SPRC Ratings Summary
SPRC Quant Ranking